leflunomide has been researched along with Lung Diseases, Interstitial in 30 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment." | 7.81 | Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | 7.73 | Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide." | 7.72 | Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004) |
| "Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA." | 6.53 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016) |
| "Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate." | 6.45 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 5.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| "Leflunomide is a disease-modifying anti-rheumatic drug that is used in patients with rheumatoid arthritis (RA), who do not respond well to standard RA treatment." | 3.81 | Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis. ( Chazan, R; Karwat, K; Langfort, R; Maskey-Warzęchowska, M; Szczepankiewicz, B; Szołkowska, M, 2015) |
| "A 60-year-old rheumatoid arthritis (RA) female with lung fibrosis was treated with leflunomide (LEF) for only 12 days, and responded well." | 3.74 | Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. ( Harada, M; Inokuma, S; Koyama, T; Niiro, H; Ohtani, R; Otsuka, T; Yoshizawa, S, 2008) |
| "We describe a 54-year-old woman with rheumatoid arthritis (RA), who developed acute respiratory failure 2 weeks after cessation of 6-week treatment with leflunomide." | 3.73 | Leflunomide induced acute interstitial pneumonia. ( Adachi, D; Akiba, H; Akiyama, Y; Hirano, M; Mimura, T; Takeishi, M, 2005) |
| "Spontaneous reports of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) treated with leflunomide, a disease-modifying antirheumatic drug (DMARD), have been appearing recently." | 3.73 | Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. ( Ernst, P; Hudson, M; Suissa, S, 2006) |
| "A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide." | 3.72 | Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. ( Haneda, K; Iwamoto, M; Kamata, Y; Kamimura, T; Masuyama, J; Minota, S; Nara, H; Okazaki, H, 2004) |
| "Leflunomide (LEF) is a frequently prescribed disease-modifying antirheumatic drug for treating RA." | 2.53 | Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review. ( Chung, KP; Huang, HN; Keng, LT; Lin, MW, 2016) |
| "The pathogenesis of DMARD-induced lung injury may have common features that need to be clarified in the future." | 2.47 | Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. ( Inokuma, S, 2011) |
| "Two patients had previous MTX-induced pneumonitis (MTX-P) prior to initiation of LEF; both died from LEIP." | 2.45 | Clinical expression of leflunomide-induced pneumonitis. ( Chikura, B; Dawson, JK; Lane, S, 2009) |
| "Leflunomide is an effective DMARD that sustains a clinical and radiological response comparable to sulfasalazine and methotrexate." | 2.45 | Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. ( Alcorn, N; Madhok, R; Saunders, S, 2009) |
| "Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
| "Leflunomide (LEF)-induced interstitial lung disease (ILD) has been reported in patients with rheumatoid arthritis." | 1.37 | Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature. ( Zhang, WX; Zhang, ZQ; Zhao, XW; Zhou, W, 2011) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 1.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (60.00) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JW | 3 |
| Chung, SW | 3 |
| Pyo, JY | 3 |
| Chang, SH | 3 |
| Kim, MU | 3 |
| Park, CH | 3 |
| Lee, JS | 6 |
| Ha, YJ | 3 |
| Kang, EH | 3 |
| Lee, YA | 3 |
| Park, YB | 3 |
| Lee, EY | 3 |
| Choe, JY | 4 |
| Cano-Jiménez, E | 1 |
| Vázquez Rodríguez, T | 1 |
| Martín-Robles, I | 1 |
| Castillo Villegas, D | 1 |
| Juan García, J | 1 |
| Bollo de Miguel, E | 1 |
| Robles-Pérez, A | 1 |
| Ferrer Galván, M | 1 |
| Mouronte Roibas, C | 1 |
| Herrera Lara, S | 1 |
| Bermudo, G | 1 |
| García Moyano, M | 1 |
| Rodríguez Portal, JA | 1 |
| Sellarés Torres, J | 1 |
| Narváez, J | 1 |
| Molina-Molina, M | 1 |
| Atzeni, F | 1 |
| Boiardi, L | 1 |
| Sallì, S | 1 |
| Benucci, M | 1 |
| Sarzi-Puttini, P | 1 |
| Rutanen, J | 1 |
| Kononoff, A | 1 |
| Arstila, L | 1 |
| Elfving, P | 1 |
| Koskela, H | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Maskey-Warzęchowska, M | 1 |
| Karwat, K | 1 |
| Szczepankiewicz, B | 1 |
| Langfort, R | 1 |
| Szołkowska, M | 1 |
| Chazan, R | 1 |
| Keng, LT | 1 |
| Lin, MW | 1 |
| Huang, HN | 1 |
| Chung, KP | 1 |
| Wang, L | 1 |
| Yang, Y | 1 |
| Jia, Y | 1 |
| Miao, H | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Chikura, B | 1 |
| Lane, S | 1 |
| Dawson, JK | 2 |
| Sawada, T | 2 |
| Inokuma, S | 4 |
| Sato, T | 2 |
| Otsuka, T | 3 |
| Saeki, Y | 2 |
| Takeuchi, T | 2 |
| Matsuda, T | 2 |
| Takemura, T | 2 |
| Sagawa, A | 2 |
| Alcorn, N | 1 |
| Saunders, S | 1 |
| Madhok, R | 1 |
| Wong, SP | 1 |
| Chu, CM | 1 |
| Kan, CH | 1 |
| Tsui, HS | 1 |
| Ng, WL | 1 |
| Lee, MA | 1 |
| Hutchinson, DG | 1 |
| McLaren, ZL | 1 |
| Zhang, WX | 1 |
| Zhou, W | 1 |
| Zhang, ZQ | 1 |
| Zhao, XW | 1 |
| Mohr, M | 1 |
| Jacobi, AM | 1 |
| McCurry, J | 1 |
| Scott, DL | 1 |
| Ito, S | 1 |
| Sumida, T | 1 |
| Kamata, Y | 1 |
| Nara, H | 1 |
| Kamimura, T | 1 |
| Haneda, K | 1 |
| Iwamoto, M | 1 |
| Masuyama, J | 1 |
| Okazaki, H | 1 |
| Minota, S | 1 |
| Nakajima, A | 1 |
| Yamanaka, H | 1 |
| Sugii, S | 1 |
| Takeishi, M | 1 |
| Akiyama, Y | 1 |
| Akiba, H | 1 |
| Adachi, D | 1 |
| Hirano, M | 1 |
| Mimura, T | 1 |
| Suissa, S | 1 |
| Hudson, M | 1 |
| Ernst, P | 1 |
| Kudo, S | 1 |
| Sugiyama, Y | 1 |
| Chida, K | 1 |
| Ogura, T | 1 |
| Yamaguchi, T | 1 |
| Miyazaki, K | 1 |
| Ochi, S | 1 |
| Harigai, M | 1 |
| Mizoguchi, F | 1 |
| Iwai, H | 1 |
| Hagiyama, H | 1 |
| Oka, T | 1 |
| Miyasaka, N | 1 |
| Ju, JH | 1 |
| Kim, SI | 1 |
| Lee, JH | 1 |
| Lee, SI | 1 |
| Yoo, WH | 1 |
| Chung, SH | 1 |
| Lee, J | 1 |
| Lee, YH | 1 |
| Lee, SS | 1 |
| Yoon, HJ | 1 |
| Yoon, CH | 1 |
| Kim, HY | 1 |
| Park, SH | 1 |
| Koyama, T | 1 |
| Ohtani, R | 1 |
| Niiro, H | 1 |
| Yoshizawa, S | 1 |
| Harada, M | 1 |
8 reviews available for leflunomide and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Topics: Antibodies, Blocking; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheum | 2013 |
Diffuse alveolar damage in a patient with rheumatoid arthritis under prolonged leflunomide treatment: A Case Report and Literature Review.
Topics: Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunom | 2016 |
Clinical expression of leflunomide-induced pneumonitis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunosuppressive Agents; | 2009 |
Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Drug Therapy, Combination; | 2009 |
Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury.
Topics: Animals; Antirheumatic Agents; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; | 2011 |
[Leflunomide for therapy of rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Is | 2005 |
[Adverse effects of DMARDs in treatment of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Sodium Thiomalate; Hematologic Diseases; H | 2005 |
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposi | 2006 |
22 other studies available for leflunomide and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Leflunomide; Lung Diseases, Interstitial; Male; | 2023 |
Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies | 2021 |
Five cases of interstitial lung disease after leflunomide was combined with methotrexate therapy.
Topics: Aged; Arthritis, Rheumatoid; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fema | 2014 |
Leflunomide-induced acute interstitial pneumonia in a patient treated for rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Fatal Outcome; Humans; Isoxazoles; Leflunomide; Lung | 2015 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Weight; Female; Humans; Isoxazoles; Japan; L | 2009 |
Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Crotonates | 2009 |
Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy.
Topics: Adult; Alveolitis, Extrinsic Allergic; Anion Exchange Resins; Antirheumatic Agents; Arthritis, Rheum | 2009 |
HRCT-proven leflunomide pneumonitis in a patient with psoriatic arthritis and normal lung function tests and chest radiography.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Isoxazoles; Leflunomide; Lung Diseases, | 2010 |
Comment on: Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Asian People; Cause of Death; Humans; Isoxazoles; Japan | 2010 |
Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Child; China; Female; Humans; IgA Vasculitis; Isoxazo | 2011 |
Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchoalveolar Lava | 2011 |
Japan deaths spark concerns over arthritis drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cause of Death; Drug Approval; Human | 2004 |
Interstitial lung disease and disease modifying anti-rheumatic drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Isoxaz | 2004 |
Interstitial lung disease associated with leflunomide.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Isoxazoles; Leflunomide; Lun | 2004 |
Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Eruptions; Human | 2004 |
Leflunomide induced acute interstitial pneumonia.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Cholestyramine Resin; Drug Therapy, Combination; Fema | 2005 |
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Isoxazoles; Leflunomide | 2006 |
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomid | 2006 |
Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Autopsy; Cholestyramine | 2006 |
Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Korea; Leflunomide; Lung Di | 2007 |
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female | 2008 |